Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

Shariful Islam, Claudia M. Espitia, Daniel O. Persky, Jennifer S. Carew, Steffan T. Nawrocki

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Despite the promising antilymphoma activity of histone deacetylase (HDAC) inhibitors as a drug class, resistance is a significant clinical issue. Elucidating the molecular mechanisms driving HDAC inhibitor resistance and/or the specific targets that are altered in drug-resistant cells may facilitate the development of strategies that overcome drug resistance and are more effective for refractory patients. We generated novel T-cell lymphoma (TCL) cell line models of acquired resistance to the HDAC inhibitor belinostat to identify potential effective therapies. Belinostat-resistant cells displayed significant cross-resistance to other HDAC inhibitors including romidepsin, panobinostat, and vorinostat. Consistent with a lack of sensitivity to HDAC inhibitors, the resistant cells failed to induce increased acetylated histones. Drug-resistant cells featured significantly decreased expression of the key antiviral mediators IRF1 and STAT1. On the basis of these findings, we investigated the efficacy of the clinical formulation of reovirus (Reolysin) in parental and drug-resistant models. Our investigation revealed that HDAC inhibitor–resistant cells displayed enhanced vulnerability to reovirus replication and cell death in both in vitro and in vivo models compared with their parental counterparts. Importantly, Reolysin also significantly increased the antilymphoma activity of belinostat in HDAC inhibitor–resistant cells. Our data demonstrate that Reolysin alone or in combination with belinostat is a novel therapeutic strategy to treat TCL patients who develop resistance to HDAC inhibitors.

Original languageEnglish (US)
Pages (from-to)5297-5310
Number of pages14
JournalBlood Advances
Issue number20
StatePublished - Oct 27 2020

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy'. Together they form a unique fingerprint.

Cite this